Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press5710.17650/1994-4098-2013-0-3-4-50-53MAMMOLOGY. TREATMENTМАММОЛОГИЯ. ЛЕЧЕНИЕTen-year adjuvant hormone therapy for breast cancer: the pros and cons (a review of literature)Адъювантная гормонотерапия рака молочной железы длительностью 10 лет: за и против (обзор литературы)PortnoyS. M.ПортнойС. М.
Russian Federation
ShendrikovaT. A.ШендриковаТ. А.
Russian Federation
shendrikova.tatyana@gmail.comN.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н.Н. Блохина РАМН», Москва220920133-4505322072014220720142013https://ojrs.abvpress.ru/ojrs/article/view/57

Tamoxifen is one of the basic drugs of adjuvant hormone therapy in patients with hormone-dependent breast tumors. The purpose of this paper is to analyze the results of randomized trials of long-term adjuvant hormone therapy for breast cancer.

ЦУ больных гормонально-зависимыми опухолями молочной железы тамоксифен является одним из основных препаратов адъю- вантной гормонотерапии. Целью данной статьи является анализ результатов 7 рандомизированных исследований по длительной адъювантной гормонотерапии рака молочной железы.

breast canceradjuvant hormone therapytamoxifenlong-term resultsрак молочной железыадъювантная гормонотерапиятамоксифенотдаленные результаты1. WHO Statistical Information System (WHOSIS). URL: http://www.who.int/whosis (дата обращения: 24.03.2010).WHO Statistical Information System (WHOSIS). URL: http://www.who.int/whosis (дата обращения: 24.03.2010).2. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Вестн РОНЦ 2011;22(3 прил 1):57.Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Вестн РОНЦ 2011;22(3 прил 1):57.3. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 1988;319(26):1681–92.Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 1988;319(26):1681–92.4. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351(9114):1451–67.Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351(9114):1451–67.5. Stewart H.J., Forrest A.P., Everington D. et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996;74(2):297–9.Stewart H.J., Forrest A.P., Everington D. et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996;74(2):297–9.6. Stewart H.J., Prescott R.J., Forrest A.P. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001;93(6):456–62.Stewart H.J., Prescott R.J., Forrest A.P. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001;93(6):456–62.7. Fisher B., Dignam J., Bryant J., Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93(9):684–90.Fisher B., Dignam J., Bryant J., Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93(9):684–90.8. Gray R.G., Rea D.W., Handley K. et al. aTTom Collaborators. aTTom (adjuvant Tamoxifen–To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor- positive (ER+) or ER untested breast cancer– Preliminary results. J Clin Oncol 2008;26(15S):513.Gray R.G., Rea D.W., Handley K. et al. aTTom Collaborators. aTTom (adjuvant Tamoxifen–To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor- positive (ER+) or ER untested breast cancer– Preliminary results. J Clin Oncol 2008;26(15S):513.9. Gray R.G., Rea D.W., Handley K. et al. aTTom Collaborative Group. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013;31(18S):5.Gray R.G., Rea D.W., Handley K. et al. aTTom Collaborative Group. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013;31(18S):5.10. Davies C., Pan H., Godwin J., et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. LancetDavies C., Pan H., Godwin J., et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet2013;381(9869):805–16.;381(9869):805–16.11. Goss P.E., Ingle J.N., Martino S. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793– 802.Goss P.E., Ingle J.N., Martino S. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793– 802.12. Jin H., Tu D., Zhao N. et al. Longerterm outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 2012;30(7):718–21.Jin H., Tu D., Zhao N. et al. Longerterm outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 2012;30(7):718–21.13. Jakesz R., Greil R., Gnant M. et al. Austrian Breast and Colorectal Cancer Study Group. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99(24):1845–53.Jakesz R., Greil R., Gnant M. et al. Austrian Breast and Colorectal Cancer Study Group. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99(24):1845–53.14. Mamounas E.P., Jeong J.H., Wickerham D.L. et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to- treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol 2008;26(12):1965–71.Mamounas E.P., Jeong J.H., Wickerham D.L. et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to- treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol 2008;26(12):1965–71.